Author

Zhilong Dong

Institutions: Lanzhou University Second Hospital, Lanzhou University

Observed institutions: Lanzhou University Second Hospital, Lanzhou University

ORCID: 0000-0002-4919-8164

Observed ORCID: 0000-0002-4919-8164

OpenAlex ID: A5129008917

Advancing CAR-T therapy in prostate cancer: overcoming the tumor microenvironment and enhancing efficacy

2026 · Zhongze Zhou, Yongfeng Lao, et al. · Frontiers in Oncology · 4

Natural killer and CAR-NK cell therapies in urological cancers: Progress, mechanistic lessons from CAR-T, and future directions

2026 · Zhongze Zhou, Kun Zhao, et al. · Critical Reviews in Oncology/Hematology · 2

Progress and challenges in CAR-T cell therapy for bladder cancer

2026 · Kun Zhao, Zhongze Zhou, et al. · Critical Reviews in Oncology/Hematology · 1

Case Report: Radical nephroureterectomy after toripalimab plus disitamab vedotin in biomarker-non-enriched upper tract urothelial carcinoma

2026 · Guohui Cheng, Quan Zhang, et al. · Frontiers in Oncology

Methodological considerations in evaluating TURP outcomes in the extreme elderly (≥ 85 years)

2026 · Zhongze Zhou, Kun Zhao, et al. · World Journal of Urology

Works count: 5

Citation count: 7

H-index: 2

I10-index: